Research Collaboration with Key Global Health Authorities and Institutions Including IVI, US FDA, and UK MHRA
SK Bioscience has successfully completed a project to establish the international standard material (ISM) for the SARS (SARS-CoV-1) virus in collaboration with international organizations.
SK Bioscience announced on the 12th that it was the only private company to participate in the "Joint Research for Establishing the International Standard Material for the SARS Virus," led by the World Health Organization (WHO), and successfully completed the project to respond to the global infectious disease crisis.
WHO previously announced the international standard material for the SARS virus in October last year, and SK Bioscience played a key role in the process by conducting immunogenicity analysis research. In addition to WHO and SK Bioscience, the project involved 12 global health authorities and institutions leading global health security, including the International Vaccine Institute (IVI), the U.S. FDA, the UK MHRA, and China's NIFDC.
International standard materials are substances used as benchmarks to compare and evaluate the quality, safety, and efficacy of vaccines. In the case of infectious diseases, without international standard materials, it is difficult to verify the efficacy of vaccines and therapeutics. Therefore, the newly announced international standard material for the SARS virus is expected to be essential in the vaccine and therapeutic development processes of research institutions worldwide.
Prior to this, SK Bioscience also participated in the WHO-led research to establish the international standard material for COVID-19 (SARS-CoV-2) in 2022.
In the global health situation facing the threat of emerging infectious diseases and the potential resurgence of existing infectious diseases, the research collaboration between SK Bioscience and WHO is gaining attention as an important example that confirms the value of innovative research and technological capabilities for improving human health.
Park Yong-wook, Head of the Bio Research Division at SK Bioscience, said, "We are pleased to have our technological capabilities recognized through participation in the WHO project and to contribute to human health," adding, "We will continue to do our best to secure infectious disease response technologies through collaboration with the global network."
Meanwhile, SK Bioscience is also carrying out the ‘100-Day Mission,’ a next pandemic response project, in cooperation with the Coalition for Epidemic Preparedness Innovations (CEPI). As part of this, it is building an mRNA vaccine platform and has recently received approval for the clinical trial plan for Phase 1/2 of the Japanese encephalitis vaccine candidate ‘GBP560,’ initiating various research and development activities.
SK Bioscience plans to continue innovative research for human health and safety in collaboration with WHO, international organizations, and research institutions.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
